Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1989 7
1990 8
1991 8
1992 5
1993 5
1994 8
1995 5
1996 4
1997 4
1998 5
1999 10
2000 7
2001 4
2002 8
2003 5
2004 5
2005 9
2006 6
2007 10
2008 9
2009 15
2010 9
2011 10
2012 14
2013 21
2014 31
2015 46
2016 47
2017 47
2018 68
2019 64
2020 78
2021 68
Text availability
Article attribute
Article type
Publication date

Search Results

571 results
Results by year
Filters applied: . Clear all
Page 1
Osteosarcoma.
Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ, Laack N. Eaton BR, et al. Pediatr Blood Cancer. 2021 May;68 Suppl 2:e28352. doi: 10.1002/pbc.28352. Epub 2020 Aug 11. Pediatr Blood Cancer. 2021. PMID: 32779875 Review.
Osteosarcoma is a rare tumor that requires complex multidisciplinary management. This paper reviews the general management and standard radiotherapy guidelines for osteosarcoma in both North America and Europe in a joined effort between the Children's Oncology Group
Osteosarcoma is a rare tumor that requires complex multidisciplinary management. This paper reviews the general management and standa
Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort.
Smeland S, Bielack SS, Whelan J, Bernstein M, Hogendoorn P, Krailo MD, Gorlick R, Janeway KA, Ingleby FC, Anninga J, Antal I, Arndt C, Brown KLB, Butterfass-Bahloul T, Calaminus G, Capra M, Dhooge C, Eriksson M, Flanagan AM, Friedel G, Gebhardt MC, Gelderblom H, Goldsby R, Grier HE, Grimer R, Hawkins DS, Hecker-Nolting S, Sundby Hall K, Isakoff MS, Jovic G, Kühne T, Kager L, von Kalle T, Kabickova E, Lang S, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Mayer-Steinacker R, Meyers PA, Nagarajan R, Randall RL, Reichardt P, Renard M, Rechnitzer C, Schwartz CL, Strauss S, Teot L, Timmermann B, Sydes MR, Marina N. Smeland S, et al. Eur J Cancer. 2019 Mar;109:36-50. doi: 10.1016/j.ejca.2018.11.027. Epub 2019 Jan 25. Eur J Cancer. 2019. PMID: 30685685 Free PMC article. Clinical Trial.
BACKGROUND: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The European and American Osteosarcoma Study (EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this rare dise
BACKGROUND: High-grade osteosarcoma is a primary malignant bone tumour mainly affecting children and young adults. The Europea …
Hematopoietic stem cell transplant in adults with acute lymphoblastic leukemia: the present state.
Saadeh SS, Litzow MR. Saadeh SS, et al. Expert Rev Hematol. 2018 Mar;11(3):195-207. doi: 10.1080/17474086.2018.1433030. Epub 2018 Feb 7. Expert Rev Hematol. 2018. PMID: 29376437 Review.
Allogeneic hematopoietic stem cell transplant (allo-HSCT) has an important role in management of acute lymphoblastic leukemia (ALL). ...Incorporation of minimal residual disease (MRD) and molecular testing will improve patient allocation. ...
Allogeneic hematopoietic stem cell transplant (allo-HSCT) has an important role in management of acute lymphoblastic le …
Case-based review: atypical teratoid/rhabdoid tumor.
Nesvick CL, Nageswara Rao AA, Raghunathan A, Biegel JA, Daniels DJ. Nesvick CL, et al. Neurooncol Pract. 2019 May;6(3):163-178. doi: 10.1093/nop/npy037. Epub 2018 Oct 5. Neurooncol Pract. 2019. PMID: 31386032 Free PMC article. Review.
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare CNS cancer that typically occurs in children younger than 3 years of age. ...
Atypical teratoid/rhabdoid tumor (AT/RT) is a rare CNS cancer that typically occurs in children younger than 3 years of age. ...
Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M. Peyvandi F, et al. J Thromb Haemost. 2020 Jun;18(6):1242-1255. doi: 10.1111/jth.14784. Epub 2020 Apr 23. J Thromb Haemost. 2020. PMID: 32115865 Free article. Review.
However, increasing use of these therapies poses challenges to clinicians and coagulation laboratories due to the lack of standardized assays for monitoring of hemostatic parameters, and the potential for misinterpretation of test results, which may jeopardize patient safety. Def …
However, increasing use of these therapies poses challenges to clinicians and coagulation laboratories due to the lack of standardized assay …
International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, Chanswangphuwana C, Efebera YA, Holler E, Litzow M, Ordemann R, Qayed M, Renteria AS, Reshef R, Wölfl M, Chen YB, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara JL, Levine JE. Harris AC, et al. Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10. doi: 10.1016/j.bbmt.2015.09.001. Epub 2015 Sep 16. Biol Blood Marrow Transplant. 2016. PMID: 26386318 Free PMC article.
Acute graft-versus-host disease (GVHD) remains a leading cause of morbidity and nonrelapse mortality after allogeneic hematopoietic cell transplantation. The clinical staging of GVHD varies greatly between transplant centers and is frequently not agreed on by …
Acute graft-versus-host disease (GVHD) remains a leading cause of morbidity and nonrelapse mortality after allogeneic hematopoietic …
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial.
Davis KL, Fox E, Merchant MS, Reid JM, Kudgus RA, Liu X, Minard CG, Voss S, Berg SL, Weigel BJ, Mackall CL. Davis KL, et al. Lancet Oncol. 2020 Apr;21(4):541-550. doi: 10.1016/S1470-2045(20)30023-1. Epub 2020 Mar 17. Lancet Oncol. 2020. PMID: 32192573 Free PMC article. Clinical Trial.
Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the following disease cohorts: rhabdomyosarcoma, Ewing sarcoma, osteosarcoma, neuroblastoma, Hodgkin lymphoma, non-Hodgkin lymphoma …
Eligible patients for part B (dose-expansion phase) were aged 1-30 years with measurable disease (by RECIST criteria) in the followin …
Real-World Issues and Potential Solutions in Hematopoietic Cell Transplantation during the COVID-19 Pandemic: Perspectives from the Worldwide Network for Blood and Marrow Transplantation and Center for International Blood and Marrow Transplant Research Health Services and International Studies Committee.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, Wood WA, Brazauskas R, Lehmann L, Pasquini MC, Seber A, Lu PH, Atsuta Y, Riches M, Perales MA, Worel N, Okamoto S, Srivastava A, Chemaly RF, Cordonnier C, Dandoy CE, Wingard JR, Kharfan-Dabaja MA, Hamadani M, Majhail NS, Waghmare AA, Chao N, Kröger N, Shaw B, Mohty M, Niederwieser D, Greinix H, Hashmi SK; WBMT and the CIBMTR Health Services and International Studies Committee. Algwaiz G, et al. Biol Blood Marrow Transplant. 2020 Dec;26(12):2181-2189. doi: 10.1016/j.bbmt.2020.07.021. Epub 2020 Jul 24. Biol Blood Marrow Transplant. 2020. PMID: 32717432 Free PMC article.
The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both developed and developing countries. Realizing the challenges as a result of this pandemic affecting the daily practice of the HCT centers and t …
The current COVID-19 pandemic, caused by SARS-CoV-2, has impacted many facets of hematopoietic cell transplantation (HCT) in both dev …
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KLB, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PCW, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MCG, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Marina NM, et al. Lancet Oncol. 2016 Oct;17(10):1396-1408. doi: 10.1016/S1470-2045(16)30214-5. Epub 2016 Aug 25. Lancet Oncol. 2016. PMID: 27569442 Free PMC article. Clinical Trial.
Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. ...One suspected unexpected serious adverse reaction was reported in the MAP group: bone marrow infarction due to methotrex …
Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisatio …
Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children's Oncology Group (COG) New Agents for Ewing Sarcoma Task Force.
Bailey K, Cost C, Davis I, Glade-Bender J, Grohar P, Houghton P, Isakoff M, Stewart E, Laack N, Yustein J, Reed D, Janeway K, Gorlick R, Lessnick S, DuBois S, Hingorani P. Bailey K, et al. F1000Res. 2019 Apr 15;8:F1000 Faculty Rev-493. doi: 10.12688/f1000research.18139.1. eCollection 2019. F1000Res. 2019. PMID: 31031965 Free PMC article. Review.
Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and young adults. Metastatic and relapsed Ewing sarcoma have poor outcomes and recurrences remain common. Owing to the poor outcomes associated …
Ewing sarcoma is a small round blue cell malignancy arising from bone or soft tissue and most commonly affects adolescents and …
571 results